Aug. 8, 2019: Casual sex partners increase among U.S. MSM; why some MSM undervalue PrEP; proteinuria prevalence and fracture risk; cannabis, cocaine, and inflammation in people living with HIV.
The U.S. Food and Drug Administration has approved a three-drug regimen to treat complicated urinary tract infections and complicated intra-abdominal infections, both of which can be especially problematic for people living with HIV.
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
For people who used cocaine after being cured of HCV, the health of their kidneys declined at a relatively rapid pace.
The effect of HIV treatment on HPV risk; bone mineral density declines in women vs. men; how hep C cure affects kidney function; when it comes to non-daily PrEP, location matters.
Having HIV infection raised the chances of impaired kidney function by three standard measures in a Dutch comparison of aging adults living with versus without HIV.
Switching from a suppressive five-drug regimen to Genvoya and Prezista proved virologically noninferior to maintaining the initial regimen at 24 weeks and virologically superior at 48 weeks.
Hepatitis C independently raised the risk of kidney disease and osteoporosis or fracture in an analysis of 5,000 people with HIV.